2The GOLD Workshop Report (Updated 2008):Global strategy for the diagnosis,management and prevention of chronic obstructive pulmonary disease.www.goldcopd.com. 被引量:1
3Hogg JC,Chu F,Utokaparch S,et al.The nature of small-airway obstruction in chronic obstructive pulmonary disease.New Engl J Med,2004,350(26):2645-2653. 被引量:1
5Barnes PJ,Celli B.Systemic manifestations and comorbidities of COPD.Eur Respir J,2009,33 (5):1165-1185. 被引量:1
6Gan WQ,Man SFP,Senthilselvan A,Sin DD.Association between chronic obstructive pulmonary disease and systemic inflammation:A systemic review and a meta-analysis.Thorax,2004,59(7):574-580. 被引量:1
7Barnes PJ.Immunology of asthma and chronic obstructive pulmonary disease.Nat Immunol Rev,2008,8(3):183-192. 被引量:1
8Boswell-Smith V,Spina D.PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.Int J Chron Obstruct Pulmon Dis,2007,2(2):121-129. 被引量:1
9Culpitt SV,de Matos C,Russell RE,et al.Effect of theophylline on induced sputum inflammatory indices neutrophil chemotaxis in COPD.Am J Respir Crit Care Med,2002,165:1371-1376. 被引量:1
10Kobayashi M,Nasuhara Y,Betsuyaku T,et al.Effect of low-dose theophylline on airway inflammation in COPD.Respirology,2004,9(2):249-254. 被引量:1
2GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989. 被引量:1
3Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946. 被引量:1
4Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012. 被引量:1
6GIEMBYCZ MA,FIELD SK. Roflumilast:first phosphodiesterase 4 inhibitor approved for treatment of COPD[J]. Drug Des Devel Ther,2010,4:147-158. 被引量:1
7BAYE J. Roflumilast(daliresp)a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease[J]. Drug Forecast,2012,37(3):149-161. 被引量:1